In clinical trials, people who took semaglutide lost an average of 15 to 20% of their body weight over the course of one year, which is a remarkable result
Dam CP (12 December 1946)
How quickly do these changes develop
Access and affordability are significant challenges, as are governmental policies, such as the current prohibition on Medicare coverage for weight loss medications in the US, restrict availability for many individuals who could benefit from these therapies
Clinical trials show that tirzepatide, a dual GLP-1 and GIP receptor agonist, produces weight loss signals earlier in many patients compared to single-mechanism GLP-1 drugs, though individual response depends on metabolism and genetic sensitivity to these pathways
Since then, a number of studies have also been conducted in human primary hepatocytes, providing evidence for the direct effect of GLP-1 binding with GLP-1R in hepatocytes on reducing liver lipids [64]